Clinically, the transgenic expression of membrane IL-15 was first evaluated in a patient with B-cell acute lymphoblastic leukemia (B-ALL) after the failure of the first two CD19-CAR T and CD22-CAR T cell therapies [85]. This evidence concerns the gene IL15 and acute lymphoblastic leukemia.